BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1828367)

  • 1. The effect of bryostatin 1 on human lymphocyte-mediated cytotoxicity.
    Tilden AB; Kraft AS
    J Immunother (1991); 1991 Apr; 10(2):96-104. PubMed ID: 1828367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors.
    Esa AH; Boto WO; Adler WH; May WS; Hess AD
    Int J Immunopharmacol; 1990; 12(5):481-90. PubMed ID: 2210911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C.
    Isakov N; Galron D; Mustelin T; Pettit GR; Altman A
    J Immunol; 1993 Feb; 150(4):1195-204. PubMed ID: 8432975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of human T lymphocytes by bryostatin.
    Hess AD; Silanskis MK; Esa AH; Pettit GR; May WS
    J Immunol; 1988 Nov; 141(10):3263-9. PubMed ID: 3263418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of bryostatin on protein kinase C-regulated functions in human T lymphocytes and epidermal keratinocytes.
    Galron D; Tamir A; Gelkop S; Grossman N; Isakov N
    Immunol Lett; 1993 Dec; 39(1):17-22. PubMed ID: 8144186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E; Gerrard JM; Greenberg AH
    Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation.
    Hocevar BA; Morrow DM; Tykocinski ML; Fields AP
    J Cell Sci; 1992 Mar; 101 ( Pt 3)():671-9. PubMed ID: 1522149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of Jurkat T cells to phorbol ester and bryostatin. Development of sublines with distinct functional responses and changes in protein kinase C activity.
    Levine BL; May WS; Tyler PG; Hess AD
    J Immunol; 1991 Nov; 147(10):3474-81. PubMed ID: 1834742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The catalytic domain of protein kinase Cdelta confers protection from down-regulation induced by bryostatin 1.
    Lorenzo PS; Bögi K; Acs P; Pettit GR; Blumberg PM
    J Biol Chem; 1997 Dec; 272(52):33338-43. PubMed ID: 9407126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of lymphokine-activated killer cell-mediated cytotoxicity by phorbol ester.
    Nishimura T; Burakoff SJ; Herrmann SH
    J Immunol; 1989 Mar; 142(6):2155-61. PubMed ID: 2646377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PMA-induced human T cell proliferation by bryostatin is associated with enhanced degradation of conventional protein kinase C (cPKC): Ca2+ signals restore mitogenic activity without abrogating enhanced cPKC degradation.
    Galron D; Tamir A; Altman A; Isakov N
    Cell Immunol; 1994 Oct; 158(1):195-207. PubMed ID: 8087865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
    Correale P; Procopio A; Celio L; Caraglia M; Genua G; Coppola V; Pepe S; Normanno N; Vecchio I; Palmieri G
    Cancer Immunol Immunother; 1992; 34(4):272-8. PubMed ID: 1371427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.
    Steube KG; Drexler HG
    Leuk Lymphoma; 1993 Jan; 9(1-2):141-8. PubMed ID: 8477194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dephosphorylation of activated protein kinase C contributes to downregulation by bryostatin.
    Lee HW; Smith L; Pettit GR; Bingham Smith J
    Am J Physiol; 1996 Jul; 271(1 Pt 1):C304-11. PubMed ID: 8760059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of phorbol ester-sensitive protein kinase C isoforms in lymphokine-activated killer cell-mediated cytotoxicity: dissociation between perforin-dependent and Fas-dependent cytotoxicity.
    Ohmi Y; Ohta A; Sasakura Y; Sato N; Yahata T; Santa K; Habu S; Nishimura T
    Biochem Biophys Res Commun; 1997 Jun; 235(3):461-4. PubMed ID: 9207176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.